Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer

G. S. Bhattacharyya; M. Walia; M. Nandi; A. Murli; S. Salim; S. Rajpurohit; S. Shinde; S. Aggarwal; P. M. Parikh

doi:10.4103/sajc.sajc_126_18

South Asian Journal of Cancer, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · South Asian J Cancer 2018; 07(02): 156-158
DOI: 10.4103/sajc.sajc_126_18

Original Article

Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer

Autor*innen

G. S. Bhattacharyya

Department of Medical Oncology, Fortis Hospital, Kolkata, West Bengal
M. Walia

Department of Medical Oncology, Max Hospital, New Delhi
M. Nandi

Department of Medical Oncology, Jaypee Hospital, Noida, Uttar Pradesh
A. Murli

Department of Medical Oncology, Sarvodaya Hospital, Faridabad, Haryana
S. Salim

Department of Oncology, Hakim Sanaullah Cancer Center, Sopore, Jammu and Kashmir
S. Rajpurohit

Department of Medical Oncology, RGCI, New Delhi
S. Shinde

Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi
S. Aggarwal

Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi
P. M. Parikh

Department of Oncology, Shalby Cancer and Research Institute, Mumbai, Maharashtra

Abstract

als PDF herunterladen

Abstract

This manuscript provides a practical and easy to use consensus recommendation to community oncologists on how to use neoadjuvant chemotherapy in triple negative breast cancer patients.

Key words

Anthracycline - BCS - BRCA - carboplatin - elderly - radiotherapy - SLNB - taxane - tumor size

PDF (378 kb)

Referenzen

References
1 von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796-804.
2 Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 2014;384:164-72.
3 Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007;CD005002.
4 Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011;17:1082-9.
5 Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015;33:304-11.
6 NCCN Guidelines for Detection. Prevention, and Risk Reduction Genetic/Familial High-Risk Assessment: Breast and Ovarian, v 2; 2016. Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf. [Last accessed on 2017 Oct 17].
7 Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015;33:13-21.
8 von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol 2014;15:747-56.
9 Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: A single-institution experience. J Clin Oncol 2011;29:3739-46.
10 Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010;28:375-9.
11 Tutt A, Ellis P, Kilbum L. TNT: A randomized phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1/2 breast cancer. San Antonio Breast Cancer Symposium. 2014. p. S3-01.
12 Enokido K, Watanabe C, Nakamura S, Ogiya A, Osako T, Akiyama F, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with an initial diagnosis of cytology-proven lymph node-positive breast cancer. Clin Breast Cancer 2016;16:299-304.
13 Mocellin S, Goldin E, Marchet A, Nitti D. Sentinel node biopsy performance after neoadjuvant chemotherapy in locally advanced breast cancer: A systematic review and meta-analysis. Int J Cancer 2016;138:472-80.